
A groundbreaking approach for spatial molecular profiling has emerged in response to the growing significance of the tumor microenvironment (TME) in immuno-oncology. This technology fills the gaps left by conventional methods, revealing compartmentalized heterogeneity crucial for predicting drug resistance and patient response in cancer treatment. A recent study introduced a novel assay-agnostic method, successfully identifying immune microenvironment signatures in breast cancer patients. Notably, it outperformed FDA-approved companion diagnostic tests, revealing two distinct physiological states unrelated to conventional markers like tumor mutational burden and PD-L1 expression.
Like
Save
Share